Patents Represented by Attorney, Agent or Law Firm Jack L. Tribble
  • Patent number: 7179898
    Abstract: The present invention discloses a human vanilloid receptor-like (VR-L) receptor.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: February 20, 2007
    Assignee: Merck & Co., Inc.
    Inventor: Timothy Peter Bonnert
  • Patent number: 7179886
    Abstract: The motilin receptor has been isolated and cloned, and nucleic acid sequences are given. Two spice variants have been identified. Also, assays for motilin receptor ligands are given. The identification of the cloned motilin receptor may be used to screen and identify compounds which bind to the receptor for use in a variety of gastric conditions, including gastric motility disorders.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 20, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Scott D. Feighner, Arthur A. Patchett, Carina Tan, Karen Kulju McKee, Douglas MacNeil, Andrew D. Howard, Sheng-Shung Pong, Roy G. Smith
  • Patent number: 7148026
    Abstract: The present invention features polypeptides and nucleic acids related to a dog MCH receptor and uses of such polypeptides and nucleic acids. The dog MCH receptor is a G protein coupled receptor whose activity is stimulated by MCH binding.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: December 12, 2006
    Assignee: Merck & Co., Inc.
    Inventor: Carina Tan
  • Patent number: 6797476
    Abstract: The present invention relates to a nonchromatographic-based process for the isolation of clinical grade plasmid DNA from bacterial cells. The exemplified methods described herein outline a scaleable, economically favorable protocol for the purification of clinical grade plasmid DNA from E. coli which includes CTAB-based precipitation of DNA in combination with adsorption of impurities to calcium silicate.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: September 28, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Russel Jackson Lander, Michael Albert Winters, Francis Jeremiah Meacle
  • Patent number: 6797492
    Abstract: A unique method is disclosed for identifying and replacing immunoglobulin surface amino acid residues which converts the antigenicity of a first mammalian species to that of a second mammalian species. The method will simultaneously change immunogenicity and strictly preserve ligind binding properties. The judicious replacement of exterior amino acid residues has no effect on the ligind binding properties but greatly alters immunogenicity.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: September 28, 2004
    Assignees: Merck & Co., Inc., United States of America
    Inventors: Bruce L. Daugherty, George E. Mark, III, Eduardo A. Padlan
  • Patent number: 6790445
    Abstract: Novel combination of preservatives (methyl and propyl parabens, benzyl alcohol, and 2-phenoxyethanol) were found to pass antimicrobial testing according to USP, BP, and EP. The new preservatives were put into vaccines using L-histidine as a buffer to keep pH at 7.0. HPLC methods were developed to analyze these preservatives and their degradation products.
    Type: Grant
    Filed: February 6, 1998
    Date of Patent: September 14, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Assunta S. Ng, Ralph J. Mancinelli, John P. Hennessey
  • Patent number: 6787351
    Abstract: An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: September 7, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Ling Chen, John W. Shiver, Andrew J. Bett, Danilo R. Casimiro, Michael J. Caulfield, Michael A. Chastain, Emilio A. Emini
  • Patent number: 6762042
    Abstract: The present invention disclosed isolated nucleic acid molecules (polynucleotides) which encode NHL, a putative DNA helicase. The present invention in turn relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding NHL, substantially purified forms of associated NHL, associated mutant proteins, and methods associated with identifying compounds which modulate NHL, which will be useful in the treatment of various neoplastic disorders. Both a genomic clone containing regulatory and intron sequences, as well as the exon structure and open reading frame of human NHL are disclosed.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: July 13, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Xiaomei Liu, Chang Bai, Michael L. Metzker
  • Patent number: 6756357
    Abstract: The variants of human ciliary neutrophic factor (hCNTF) according to the present invention are characterized by substitution of phenylalanine 152 and/or lysine 155 with alanine. These variants have biological properties that render them important as the active principles of drugs for the treatment of diseases and pathologies involving the nervous system or other pathologies involving cells responding to the CNTF. FIG. 2 shows the results of simulation of haptoglobin secretion from HepG2 cells by CNTF and the variants described in the invention.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: June 29, 2004
    Assignee: Istituto di Richerche di Biologia Molecolare di Angeletti S.p.A.
    Inventors: Ralph Laufer, Annalise Di Marco
  • Patent number: 6753419
    Abstract: The subject matters of this invention are the hormone-dependent forms of Rep 78 and Rep 68 proteins of the Adeno-associated virus (AAV), obtained by the fusion of their specific mutants with the hormone binding domain (HBD) of steroid hormone receptors, and the DNA sequences coding for them. The invention also refers to a method for the hormonal regulation of the activity of the fusion products Rep78/68-HBD, inserted into eucaryotic cells utilizing viral or non-viral systems, in order to direct the stable integration of DNA sequences in specific regions of the host human genome for therapeutic purposes. The fusion products Rep78/68-HBD are also utilized to generate viral hybrid vectors (i.e. adenovirus vectors AAV) and for generating recombinant vectors AAV.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: June 22, 2004
    Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Carlo Toniatti, Cira Rinaudo, Gennaro Ciliberto
  • Patent number: 6750041
    Abstract: A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: June 15, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Gregory Franklin Hollis, George E. Mark
  • Patent number: 6746858
    Abstract: This invention provides the murD gene of Streptococcus pyogenes. Purified and isolated MurD recombinant proteins are also provided. Nucleic acid sequences which encode functionally active MurD proteins are described. Assays for the identification of modulators of the expression of murD and inhibitors of the activity of MurD, are also provided.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: June 8, 2004
    Assignee: Merck & Co. Inc.
    Inventors: Mohammed El-Sherbeini, Kenny Kin Wong
  • Patent number: 6743622
    Abstract: A specific locus in the genome of a murine host cell is identified which causes high levels of recombinant gene expression following stable integration, via homologous recombination, of the recombinant gene into the specific chromosomal locus. The selection of a favorable genome locus for the insertion and expression of a recombinant gene is disclosed, as are DNA vectors and host cells.
    Type: Grant
    Filed: November 7, 1996
    Date of Patent: June 1, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Gregory Franklin Hollis, George E. Mark
  • Patent number: 6733993
    Abstract: First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: May 11, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Emilio A. Emini, Rima Youil, Andrew J. Bett, Ling Chen, David C. Kaslow, John W. Shiver, Timothy J. Toner, Danilo R. Casimiro
  • Patent number: 6689574
    Abstract: Provided is a method of identifying agonists and antagonists of nuclear receptors that comprises measuring agonist-dependent fluorescence resonance energy transfer (FRET) between a fluorescently labeled nuclear receptor or ligand binding domain and fluorescently labeled CREB-binding protein (CBP), p300, other nuclear co-activator, or binding portion thereof. The method is simple, rapid, and inexpensive. Nuclear receptors and nuclear receptor co-activators labeled with fluorescent reagents for use in the above-described method are also provided.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Richard T. Cummings, David E. Moller, Jeffrey D. Hermes, Gaochao Zhou
  • Patent number: 6689761
    Abstract: The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey A. Chodakewitz, Emilio A. Emini
  • Patent number: 6689873
    Abstract: This invention concerns nucleic acid encoding for rat agouti related protein. Agouti related protein is a neuropeptide that may play a role in the central regulation of feeding behavior and energy metabolism via interactions with the melanocortin pathways. This invention also relates to assays utilizing the novel nucleic acid of this invention.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Leonardus H. T. Van der Ploeg, Xiaoming Guan, Hong Yu, Prashant G. Trivedi
  • Patent number: 6667163
    Abstract: The present invention provides polynucleotides and polypeptides of a murine sphingosine-1-phosphate phosphatase, referred to herein as mSPP1. The polynucleotides and polypeptides are used to further provide expression vectors, host cells comprising the vectors, probes and primers, antibodies against the mSPP1 protein and polypeptides thereof, assays for the presence or expression of mSPP1 and assays for the identification of compounds that interact with mSPP1.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: December 23, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Suzanne M. Mandala, Rosemary A. Thornton
  • Patent number: 6660467
    Abstract: The subject of the present invention are variants of ciliary neurotrophic factor with enhanced receptor selectivity (CNTFR), useful for the treatment of diseases and disorders including motor neuron diseases and muscle degenerative diseases. Another subject of the invention is to provide a method for identifying the above mentioned CNTF variants. The hCNTF variants with the amino acid substitutions in accordance with the present invention, have a reduced ability, as compared to the human CNTF, to elicit biological effects through soluble CNTFR, without affecting its ability to activate membrane-bound neuronal CNTF receptors, thereby improving its therapeutic properties. FIG. 1 shows the reduced CNTFR binding affinity of a CNTF variant according to the invention (IA-CNTF; SEQ ID NO: 2). It is evident that the binding affinity of this variant to the CNTFR is reduced as compared to the wild-type human CNTF molecule.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: December 9, 2003
    Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Isabelle Gloaguen, Annalise Di Marco, Anna De Martis, Ralph Laufer, Isabella Saggio
  • Patent number: 6656719
    Abstract: Defined serum-free, low protein media (LPKM), that supports 1) Vero cell growth for up to 20 passages, 2) Vero cell growth on microcarriers and 3) rotavirus production is provided. Maximum cell densities attained are 60-100% of that in serum-containing medium; the doubling time is equal to that for cells in serum containing medium. Rotavirus titers achieved in LPKM-1 are 50-100% of the serum-containing process. Finally, since LPKM-1 contains no animal-sourced proteins, the problems associated with the serum-containing rotavirus production process (i.e. lengthy wash steps before infection, potential introduction of adventitious agents and lot-to-lot variability) can be avoided; while maintaining nearly equivalent product titers.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: December 2, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Sandra L. Gould, David K. Robinson, Daniel J. Distefano, T. Craig Seamans